Doxercalciferol
Doxercalciferol Uses, Dosage, Side Effects, Food Interaction and all others data.
Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2. Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease. Doxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc.
| Trade Name | Doxercalciferol |
| Availability | Prescription only |
| Generic | Doxercalciferol |
| Doxercalciferol Other Names | 1-Hydroxyergocalciferol, 1-Hydroxyvitamin D2, 1α-hydroxyvitamin D2, Doxercalciferol, Doxercalciferolum, Doxercalciférolum |
| Related Drugs | cinacalcet, Sensipar, paricalcitol, Zemplar, Hectorol |
| Weight | 2mcg/ml, 0.5mcg, 1mcg, 2.5mcg |
| Type | Intravenous solution, oral capsule, oral/injection |
| Formula | C28H44O2 |
| Weight | Average: 412.6478 Monoisotopic: 412.334130652 |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Doxercalciferol is a synthetic vitamin D2 analog used to treat secondary hyperparathyroidism in patients with chronic kidney disease with or without therapy of dialysis.
Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic kidney disease.
Doxercalciferol is also used to associated treatment for these conditions: Secondary Hyperparathyroidism (SHPT)
How Doxercalciferol works
Calcitriol (1α,25-(OH)2D3) and 1α,25-(OH)2D2 regulate blood calcium at levels required for essential body functions. Specifically, the biologically active vitamin D metabolites control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. They act directly on bone cells (osteoblasts) to stimulate skeletal growth, and on the parathyroid glands to suppress PTH (parathyroid hormone) synthesis and secretion. These functions are mediated by the interaction of these biologically active metabolites with specific receptor proteins in the various target tissues. In patients with chronic kidney disease (CKD), deficient production of biologically active vitamin D metabolites (due to lack of or insufficient 25-hydroxyvitamin D-1-alpha-hydroxylase activity) leads to secondary hyperparathyroidism, which contributes to the development of metabolic bone disease.
Food Interaction
- Avoid antacids. Specifically, avoid magnesium-containing antacids as co-administration with doxercalciferol increases the risk of hypermagnesemia.
Doxercalciferol Drug Interaction
Major: sucralfate, sucralfate, cholecalciferol, cholecalciferolModerate: sevelamer, sevelamerUnknown: darbepoetin alfa, darbepoetin alfa, aspirin / caffeine, aspirin / caffeine, nebivolol, nebivolol, ciprofloxacin, ciprofloxacin, epoetin alfa, epoetin alfa, metoprolol, metoprolol, cinacalcet, cinacalcet
Doxercalciferol Disease Interaction
Half Life
32 to 37 hours.
Innovators Monograph
You find simplified version here Doxercalciferol
